A5038444798- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Viral Infections and Immunology Research
- Biosimilars and Bioanalytical Methods
- SARS-CoV-2 and COVID-19 Research
- Musculoskeletal synovial abnormalities and treatments
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Health Systems, Economic Evaluations, Quality of Life
- Lymphoma Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Cancer Treatment and Pharmacology
- Pain Mechanisms and Treatments
- Spondyloarthritis Studies and Treatments
- Anesthesia and Pain Management
- Peripheral Neuropathies and Disorders
- HER2/EGFR in Cancer Research
- Pharmaceutical studies and practices
- CAR-T cell therapy research
- Phonocardiography and Auscultation Techniques
- Dermatology and Skin Diseases
- Urticaria and Related Conditions
- Respiratory and Cough-Related Research
Leeds Teaching Hospitals NHS Trust
2010-2024
York Teaching Hospital NHS Foundation Trust
2015-2024
Chapel Allerton Hospital
2006-2024
NIHR Leeds Musculoskeletal Biomedical Research Unit
2008-2024
University of Leeds
2008-2024
University of Manchester
2023
Manchester Academic Health Science Centre
2023
NIHR Manchester Biomedical Research Centre
2023
Versus Arthritis
2023
Manchester University NHS Foundation Trust
2023
Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated rituximab. However, incidence and severity breakthrough infections unbiased samples specific rheumatic musculoskeletal are largely unknown. We aimed to assess SARS-CoV-2 infection, compare rates moderate-to-severe any severe infection event, evaluate predictors outcomes rituximab.We did a retrospective cohort study all rituximab-treated single centre Leeds,...
<h3>Objectives</h3> Patients can fulfil clinical criteria for remission, yet still have evidence of synovitis detectable clinically and by ultrasound, this is associated with structural damage. Stricter remission may more accurately reflect true (no synovitis). This hypothesis was examined studying patients using stringent thresholds determining their levels ultrasound synovitis. <h3>Methods</h3> Rheumatoid arthritis a disease activity score in 28 joints (DAS28) ≤2.6 at least 6 months were...
Combination therapy with methotrexate (MTX) and tumour necrosis factor (TNF) blockade has increased remission rates in patients rheumatoid arthritis. However, there are no guidelines regarding cessation of therapy. There is a need for markers predictive sustained following TNF blocker therapy.Patients (DAS28 <2.6) treated MTX as initial or delayed were recruited. Joints assessed grey scale synovitis power Doppler (PD) activity. Immunological assessment involved advanced six-colour flow...
The treatment target for patients with rheumatoid arthritis (RA) is remission. Imaging techniques and remission criteria may identify at risk of flare associated consequences. This study aimed to determine the clinical, functional imaging associations disease in RA any effect on long-term outcomes.RA clinical as determined by their treating rheumatologist were assessed using criteria, imaging, quality life measures over 12 months. Flare was defined increase activity requiring a change...
<h3>Objectives:</h3> Abatacept is the only agent currently approved to treat rheumatoid arthritis (RA) that targets co-stimulatory signal required for full T-cell activation. No studies have been conducted on its effect synovium, primary site of pathology. The aim this study was determine synovial abatacept in patients with RA and an inadequate response tumour necrosis factor alpha (TNFα) blocking therapy. <h3>Methods:</h3> This first mechanistic incorporated both dynamic contrast-enhanced...
Abstract Objective For patients with rheumatoid arthritis (RA) in remission who are receiving disease‐modifying antirheumatic drugs (DMARDs), radiographic progression correlates imaging‐detected synovitis as measured by power Doppler activity. In contrast, disease the combination of tumor necrosis factor (TNF) blockade methotrexate (MTX) (combination treatment) have reduced damage for equivalent clinical state. We undertook this study to determine whether difference outcome is a result more...
Abstract Objectives Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of ‘Th2’ cytokines IL-13. It has a license to treat atopic eczema was recently linked emergent enthesitis psoriasis. We investigated cellular functional basis for how IL-4/IL-13 regulates IL-23–IL-17 axis in entheseal stromal, myeloid lymphocyte cells. Methods Immunohistochemistry performed on healthy enthesis samples from patients undergoing elective spinal surgery investigate tissue IL-4R expression cytokine...
Objectives To assess antibody and T cell responses to SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on disease-modifying antirheumatic drugs (DMARDs). Methods This prospective study recruited 100 RA a variety of DMARDs for analysis, pre-vaccination 4 weeks post-vaccination. Positive response was defined as sera IgG binding ≥1 antigen. Those that remained seronegative after first were retested second vaccination; if still three. A an ELISpot count ≥7 interferon...
Objective To investigate the prevalence of poly‐refractory rheumatoid arthritis (RA) defined as failure all biological (b)/targeted synthetic (ts)‐disease‐modifying drugs (DMARDs). further whether patients with persistent inflammatory refractory RA (PIRRA) and noninflammatory (NIRRA), determined by objective ultrasound (US) synovitis, have distinct clinical phenotypes in both EULAR difficult‐to‐treat (D2T‐RA) groups. Methods A cross‐sectional study 1,591 on b/tsDMARDs that evaluated D2T‐RA...
Physiotherapists often use adventitious lung sounds(ALS), i.e., wheeze(Wh) and crackle(Cr), to monitor respiratory techniques in acute obstructive(AO) restrictive(AR) patients. ALS are responsive bronchodilators however, evidence regarding its usefulness physiotherapy(RP) is scarce. This study aimed assess the responsiveness of one session RP applied obstructive restrictive included breathing retraining airway clearance techniques. Sound recordings were acquired with a digital stethoscope...
Objective. To ascertain whether a 1-year remission induction therapy with an infliximab–MTX (INF–MTX) combination in patients early RA provided sustained benefit after INF cessation compared conventional treatment.
Background Hand involvement is an early manifestation of systemic sclerosis (SSc), culprit diagnosis and classification, recognised major driver disability. Impairment hand function burdens both limited diffuse cutaneous subsets therefore could be targeted as ‘basket’ endpoint in SSc. Nevertheless, its natural history current standard care not well characterised, limiting the design trials. The aim this study to describe prevalence, clinical factors associated with deterioration a...
To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with RA.Between October 2017 and 2019, all on RTX-O our centre requiring re-treatment were switched RTX-B unless declined by patient or specified treating clinician. Switch strategy effectiveness was assessed retrospectively using DAS28-CRP(3) RTX retention, remaining as a comparator group.The number switching 255/337 (75.7%) while 82 (24.3%) remained RTX-O. There no difference 4...
<h3>Background</h3> Previous research has shown that cessation of TNFi in patients with established RA who are sustained remission is associated an increased risk flare. However, it still unknown whether the reintroduction those flare following any effects on long term outcome. <h3>Objectives</h3> 1-To assess 12 month outcomes (DAS28 < 2.6) at baseline. 2- To compare restated after unsuccessful continued treatment. <h3>Methods</h3> Patients for ≥ 6 months were a combination methotrexate...
There is accumulating evidence that early and aggressive treatment of rheumatoid arthritis may lead to enhanced sustained clinical outcomes. The goal therapy in remission. Tumor necrosis factor a pivotal pro-inflammatory cytokine arthritis. Infliximab, chimeric murine human antitumor monoclonal antibody, was the first tumor blocking agent be used humans. Blockade occupies central hierarchal role now several other chronic inflammatory conditions. Although there are still many limitations...
<h3>Background:</h3> We recently reported that 2.7% of rheumatoid arthritis (RA) cases were polyrefractory (failure/tolerance all b/tsDMARD classes). However, 40% D2T-RA patients including RA (PFRA), lacked objective joint inflammation signs on ultrasound (US)- termed non-inflammatory refractory (NIRRA) whilst the remaining had US determined persistent inflammatory (PIRRA). [1] EULAR suggests rapid radiographic progression (radiographic above 5 units per year according to modified Sharp/van...